Evolution of Acquired Drug Resistance in BRAF-Mutant Melanoma
Melanoma is a highly aggressive type of skin cancer. Metastatic melanoma tumors have historically featured a particularly poor prognosis and have often been considered incurable. Recent advances in targeted therapeutic interventions have radically changed the landscape in metastatic melanoma managem...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-10-01
|
| Series: | DNA |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-8856/4/4/25 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850241747136806912 |
|---|---|
| author | Josué Ballesteros-Álvarez Ana M. Blázquez-Medela |
| author_facet | Josué Ballesteros-Álvarez Ana M. Blázquez-Medela |
| author_sort | Josué Ballesteros-Álvarez |
| collection | DOAJ |
| description | Melanoma is a highly aggressive type of skin cancer. Metastatic melanoma tumors have historically featured a particularly poor prognosis and have often been considered incurable. Recent advances in targeted therapeutic interventions have radically changed the landscape in metastatic melanoma management, significantly increasing the overall survival of patients. Hyperactive BRAF is the most common mutational event found in metastatic melanoma and its inhibition has proven to be a successful approach in a number of patients. Unfortunately, initial tumor retreat is followed by relapse in most cases, highlighting the elusiveness of finding a widely effective treatment. Melanoma tumors often carry a particularly high number of mutations in what is known as a high level of inter- and intra-patient tumor heterogeneity, driving resistance to treatment. The various mutations that are present in these tumors, in addition to impacting the root cause of the malignancy and the potential for therapeutic interventions, have also been known to arise during tumor clonal evolution leading to the establishment of drug resistance, a major issue in melanoma management. |
| format | Article |
| id | doaj-art-d4e5c33b97264eb29d91f0534f113041 |
| institution | OA Journals |
| issn | 2673-8856 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | DNA |
| spelling | doaj-art-d4e5c33b97264eb29d91f0534f1130412025-08-20T02:00:32ZengMDPI AGDNA2673-88562024-10-014435536910.3390/dna4040025Evolution of Acquired Drug Resistance in BRAF-Mutant MelanomaJosué Ballesteros-Álvarez0Ana M. Blázquez-Medela1Buck Institute for Research on Aging, Novato, CA 94945, USADepartment of Basic Medical Sciences, Western University of Health Sciences, Pomona, CA 91766, USAMelanoma is a highly aggressive type of skin cancer. Metastatic melanoma tumors have historically featured a particularly poor prognosis and have often been considered incurable. Recent advances in targeted therapeutic interventions have radically changed the landscape in metastatic melanoma management, significantly increasing the overall survival of patients. Hyperactive BRAF is the most common mutational event found in metastatic melanoma and its inhibition has proven to be a successful approach in a number of patients. Unfortunately, initial tumor retreat is followed by relapse in most cases, highlighting the elusiveness of finding a widely effective treatment. Melanoma tumors often carry a particularly high number of mutations in what is known as a high level of inter- and intra-patient tumor heterogeneity, driving resistance to treatment. The various mutations that are present in these tumors, in addition to impacting the root cause of the malignancy and the potential for therapeutic interventions, have also been known to arise during tumor clonal evolution leading to the establishment of drug resistance, a major issue in melanoma management.https://www.mdpi.com/2673-8856/4/4/25melanomadrug resistancemutationtumor clonal evolutionBRAFMITF |
| spellingShingle | Josué Ballesteros-Álvarez Ana M. Blázquez-Medela Evolution of Acquired Drug Resistance in BRAF-Mutant Melanoma DNA melanoma drug resistance mutation tumor clonal evolution BRAF MITF |
| title | Evolution of Acquired Drug Resistance in BRAF-Mutant Melanoma |
| title_full | Evolution of Acquired Drug Resistance in BRAF-Mutant Melanoma |
| title_fullStr | Evolution of Acquired Drug Resistance in BRAF-Mutant Melanoma |
| title_full_unstemmed | Evolution of Acquired Drug Resistance in BRAF-Mutant Melanoma |
| title_short | Evolution of Acquired Drug Resistance in BRAF-Mutant Melanoma |
| title_sort | evolution of acquired drug resistance in braf mutant melanoma |
| topic | melanoma drug resistance mutation tumor clonal evolution BRAF MITF |
| url | https://www.mdpi.com/2673-8856/4/4/25 |
| work_keys_str_mv | AT josueballesterosalvarez evolutionofacquireddrugresistanceinbrafmutantmelanoma AT anamblazquezmedela evolutionofacquireddrugresistanceinbrafmutantmelanoma |